A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

To obtain absorption, metabolism and excretion data for parent drug and any metabolites.

Inclusion Criteria:

• Healthy males
• Body mass index (BMI) between 18.5 and 25.0 kg/m2, inclusive
• Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Exclusion Criteria:

• Subjects who have a significant history of alcoholism or drug/chemical abuse, as determined by the Investigator.
• Subjects who smoke, or who have used nicotine within 3 months prior to screening..
• Subjects who have a significant history of drug allergy, as determined by the Investigator.
• Subjects who have any clinically significant abnormal physical examination finding.
• Subjects who have any clinically significant medical history, as determined by the Investigator.
• Subjects who are exposed to radiation as a result of their occupation.
• Subjects who have had an X ray or CT scan, or who have participated in any trial involving a radiolabelled investigational product or have been exposed to radiolabelled substances within 12 months prior to dose administration.